Abstract: The invention relates to optical devices for producing and/or transforming polarized electromagnetic emission by means of anisotropic absorption and/or optical rotation effects and/or birefringence and can be used as different polarizers (dichroic, reflecting), lagging layers (retarders), liquid-crystal displays and indicators and also for producing polarizing glass for building construction and for sun and antiglare glasses, masks, aprons and faceplates. The inventive optical device is based on at least one molecularly oriented layer of a low-molecular or oligomeric dichroic material which can form a stable lyotropic liquid crystal structure. The projection of at least one anisotropically absorbing fragment of a molecule of the dichroic material on the surface of the molecularly oriented layer of a dipole moment of optical transition is disposed in a parallel position to the optical axis of the molecularly oriented layer at least within several ranges of wavelength of the electromagnetic emission.

Abstract: The present invention relates to medicine, more concretely to photodynamic therapy, and may be used in oncology and dermatology. A method is proposed for photodynamic therapy of pathological surface formations, which comprises sensitizing a surface of the pathological area by superposing an applicator containing 5-aminolevulinic acid, and irradiating the sensitized area with therapeutic optical radiation in the spectral range of 625-700 nm, wherewith an applicator is used which is transparent in the spectral range of at least 625-700 nm, and irradiation is carried out through the applicator. Wherewith therapeutic irradiation is carried out under control of the intensity of fluorescence of the tissues of the pathological area by irradiation of the tissues in the spectral range of 625-635 nm and measurement of the intensity of fluorescence in the range of 635-700 nm through the applicator.

Abstract: The invention relates to light polarizers and devices for displaying information based on said polarizers, in particular to a liquid crystal indicating (LCI) element, and can be used on flat liquid-crystal displays, including those of the projection type, luminairs, optical modulators, matrix systems of light modulation, etc. The objective of the invention is to provide a highly efficient polarizer providing an improved brightness and color saturation of an LCI element based on such polarizer. This objective is to be attained by using, in manufacture of a polarizer and an LCI element based on such polarizer, at least one birefringent anisotropically absorbing layer having at least one refraction index that grows as the polarized light wavelength increases., i.e., having the abnormal dispersion. The use of said layer allows creation of polarizers of both the dichroic and interference types.

Abstract: A method for regional administration of preparations during the therapy of liver tumor, comprising administering a preparation into a branch of the portal vein with the simultaneous occlusion of afferent and efferent lobe vessels (branches of the portal vein proximal the place of puncture, branches of the hepatic artery and lobar hepatic vein) for 5–15 minutes. During catalytic therapy, it is preferable to use Teraphtalum as the preparation and to administer ascorbic acid after termination of occlusion. During photodynamic therapy, it is preferable to use photosens as the preparation and to carry out irradiation of the tumor after 10–35 minutes. This method of administration provides for the predominant accumulation of the preparations in the target lobe (tumor carrier lobe) of the liver, their low penetration into the systemic blood flow, which makes it possible to reduce the dose of the preparation and its general toxicity.

Abstract: The invention relates to light polarizers and devices for displaying information based on said polarizers, in particular to a liquid crystal indicating (LCI) element, and can be used on flat liquid-crystal displays, including those of the projection type, luminairs, optical modulators, matrix systems of light modulation, etc. The objective of the invention is to provide a highly efficient polarizer providing an improved brightness and color saturation of an LCI element based on such polarizer. This objective is to be attained by using, in manufacture of a polarizer and an LCI element based on such polarizer, at least one birefringent anisotropically absorbing layer having at least one refraction index that grows as the polarized light wavelength increases., i.e., having the abnormal dispersion. The use of said layer allows creation of polarizers of both the dichroic and interference types.

Abstract: The objective of the invention is to provide an highly efficient polarizer providing an improved brightness and color saturation of a LCI element based on such polarizer. This objective is to be attained by using, in manufacture of a polarizer and a LCI element based on such polarizer, at least one birefringent anisotropically absorbing layer having at least one refraction index that grows as the polarized light wavelength increases, i.e. having the abnormal dispersion. The use of said layer allows to create polarizers of both the dichroic and interference types. Further, the use of said layer allows to create a polarizer that provides, in a relatively simple design, conversion of practically all energy of a non-polarized radiation into the polarized radiation.

Abstract: Thee present invention relates to medicine, more concretely to photodynamic therapy, and may be used in oncology and dermatology.

Abstract: A method for regional administration of preparations during the therapy of liver tumor, comprising administering a preparation into a branch of the portal vein with the simultaneous occlusion of afferent and efferent lobe vessels (branches of the portal vein proximal the place of puncture, branches of the hepatic artery and lobar hepatic vein) for 5-15 minutes.

Abstract: The invention relates to the field of biology and medicine, in particular to suppression of the growth of malignant tumors.The object of the present invention is to find more effective and less toxic drugs for suppression of tumor growth.The essence of the proposed invention is that in order to suppress tumor growth, a drug consisting of a biogenic reductant and a complex of cobalt or iron with substituted phthalocyanines (I) or naphthalocyanines (II) is used. ##STR1## where R.dbd.COONa, SO.sub.3 Na, CH.sub.2 C.sub.5 H.sub.5 N.sup..sym. Cl.sup.-, CH.sub.2 (NH.sub.2).sub.2 S.sup..sym. CCl.sup.-.Use of the proposed drug makes it possible to suppress effectively the growth of a wide range of malignant tumors, in particular to achieve the suppression of proliferation of cancer cells (in vitro), inhibition of the growth of tumors in mice (in vivo) and a substantial increase in their life-span, including that obtained in comparison with use of the prototype.

Abstract: Novel dinaphthyl derivatives characterized by the general formula ##SPC1##Where X.sub.1, X.sub.2 and X.sub.3, X.sub.4 represent a group O=C-Y-C=O, wherein Y is an imino group, either unsubstituted or containing one of the following substituents: alkyl, cycloalkyl, aryl, and heterocycle, either unsubstituted or containing one of the following substituents: amino group, halogen, alkoxy, alkyl; or one X of the pair X.sub.1, X.sub.2 and one X of the pair X.sub.3, X.sub.4 represent a group --C=O and then the other X is in the benzimidazole or perinone cycle, the compounds of said formula being either symmetrical or non-symmetrical with respect to the 1,1'-bond.Said derivatives are produced by reacting 1,1'-dinaphthyl-4,4',5,5',8,8'-hexacarboxylic acid with a compound of the general formula R-NH.sub.2, where R is hydrogen, alkyl, cycloalkyl, aryl, or heterocycle, either unsubstituted or containing one of the substituents: amino group, halogen, alkoxy, alkyl, in a solvent or in excess compound of the formula R-NH.

Abstract: Novel dinaphthyl derivatives characterized by the general formula ##SPC1## heterocycle,Where X.sub.1, X.sub.2, and X.sub.3, X.sub.4 represent a group O=C--Y--C=O, wherein Y is an imino group, either unsubstituted or containing one of the following substituents: alkyl, cycloalkyl, aryl, and neterocycle, either unsubstituted or containing one of the following substituents: amino group, halogen, alkoxy, alkyl; or one X of the pair X.sub.1, X.sub.2 ; and one X of the pair X.sub.3, X.sub.4 represent a group --C=O and then the other X is in the benzimidazole or perinone cycle, the compounds of said formula being either symmetrical or non-symmetrical with respect to the 1,1'-bond.Said derivatives are produced by reacting 1,1'-dinaphthyl-4,4',5,5',8,8' hexacarboxylic acid with a compound of the general formula R-NH.sub.